We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- MedPacto's Vactosertib demonstrated a 36.4% objective response rate in Phase 1 osteosarcoma trials, including one complete remission case, representing more than three times the efficacy of existing treatments. - The company has expanded its Phase 2 clinical trial to six major Korean hospitals and received compassionate use requests from prominent US medical institutions including Johns Hopkins and Stanford. - Vactosertib has received orphan drug designation in the US and Europe, along with FDA Fast Track designation, with Breakthrough Therapy designation discussions ongoing.
